NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE1025.4025.95 (+2.6 %)
PREV CLOSE ( ) 999.45
OPEN PRICE ( ) 1007.70
BID PRICE (QTY) 1024.30 (35)
OFFER PRICE (QTY) 1025.40 (46)
VOLUME 54327
TODAY'S LOW / HIGH ( )1000.70 1046.75
52 WK LOW / HIGH ( )563 1107.85
NSE1025.0026.4 (+2.64 %)
PREV CLOSE( ) 998.60
OPEN PRICE ( ) 1006.65
BID PRICE (QTY) 1024.45 (11)
OFFER PRICE (QTY) 1025.00 (40)
VOLUME 733469
TODAY'S LOW / HIGH( ) 1000.75 1047.40
52 WK LOW / HIGH ( )563 1108.35
Peer Companies Price () Chg () Chg (%) EPS () TTM P/E Volume (000's) 1 Year Return (%)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.